42 results about "Ornithine decarboxylase" patented technology

The present invention provides methods and compositions for modulating polyamine pathway activity as a means for ameliorating neurodegenarative disorders. In particular, for ameliorating the symptoms or onset of amyotrophic lateral sclerosis (ALS) by modulating the gene and protein products involved the polyamine pathway, such as by inhibiting the enzyme, ornithine decarboxylase (ODC), involved in the synthesis of the polyamine, putrescine. Compositions and methods are disclosed for inhibiting the polyamine pathway producing lower polyamine levels resulting in a beneficial effect on ALS. This can be accomplished by using modulating agents such as analogs, or polyamine analogs, and antiproliferative drugs. Screening assays for pharmacological agents that are capable of decreasing polyamine levels and / or reducing cell proliferation are also disclosed.

In accordance with the present invention, there are provided novel Siah-Mediated-Degradation-Proteins (SMDPs) and / or SCF-Complex Proteins (SCPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SMDPs and / or SCPs can be employed in a variety of ways, for example, for the production of anti-SMDP and / or SCP antibodies thereto, in therapeutic compositions, and methods employing such proteins and / or antibodies for drug screening, functional genomics and other applications. Also provided are transgenic non-human mammals that express the invention protein. Also provided are compositions and methods for targeting the destruction of selected polypeptides in eukaryotic cells based on the ubiquitin-independent mechanism by which ornithine decarboxylase is degraded by the 26S proteasome.

Green fluorescent protein (GFP) is widely used as a reporter in determining gene expression and protein localization. The present invention provides fusion proteins with a half life of ten hours or less with several embodiments having half lives of 4 hours or less. Such proteins may be constructed by fusing C-terminal amino acids of the degradation domain of mouse ornithine decarboxylase (MODC), which contains a PEST sequence, to the C-terminal end of an enhanced variant of GFP (EGFP). Fluorescence intensity of the fusion protein in transfected cells is similar to that of EGFP, but the fusion protein, unlike EGFP, is unstable in the presence of cycloheximide. Specific mutations in the MODC region have resulted in mutants with varying half lives, useful for a variety of purposes.

The invention relates to a genetically-engineered strain streptomyces diastatochromogenes with high production of epsilon-polylysine. The streptomyces diastatochromogenes is obtained by over-expressing three key genes, in different metabolic pathways, of a succinate dehydrogenase gene sdhB, a lysine / ornithine decarboxylase gene dcdA and an asparagine synthetase gene asnO in streptomyces diastatochromogenes TUST separately. According to the genetically-engineered strain streptomyces diastatochromogenes with high production of the epsilon-polylysine, by over-expressing the key genes in the different metabolic pathways, the genetically-engineered recombinant strain is obtained, and an experiment proves that the epsilon-polylysine-producing capability of the streptomyces genetically-engineeredstrain is improved compared with that of the original strain streptomyces diastatochromogenes TUST in the same situation, so that the excellent strain is provided for production of epsilon-polylysine.

The present invention relates to a putrescine-producing microorganism and a method for producing putrescine using the same. To be more specific, the present invention is directed to a microorganism given the ability to produce putrescine which is generated by blocking a biosynthetic pathway from ornithine to arginine, increasing the intracellular level of glutamate, enhancing the biosynthetic pathway of ornithine from glutamate, and introducing extracellular ornithine decarboxylase; and a method for producing putrescine by using the microorganism.

One example embodiment is a method of treating lung carcinoma in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of an arginine reducing compound and a therapeutically effective amount of an ornithine decarboxylase (ODC) inhibitor to provide a combination therapy that has a synergistic therapeutic effect compared to an effect of the arginine reducing compound and an effect of the ODC inhibitor, in which each of the arginine reducing compound and the ODC inhibitor is administered alone.

In accordance with the present invention, there are provided novel Siah-Mediated-Degradation-Proteins (SMDPs) and / or SCF-Complex Proteins (SCPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SMDPs and / or SCPs can be employed in a variety of ways, for example, for the production of anti-SMDP and / or SCP antibodies thereto, in therapeutic compositions, and methods employing such proteins and / or antibodies for drug screening, functional genomics and other applications. Also provided are transgenic non-human mammals that express the invention protein. Also provided are compositions and methods for targeting the destruction of selected polypeptides in eukaryotic cells based on the ubiquitin-independent mechanism by which ornithine decarboxylase is degraded by the 26S proteasome.

The invention belongs to the technical field of chiral compounds biological transformation separation, in particular relates to a method for preparing chiral organic coumounds and a method for preparing D-ornithine and putrescine, and is also suitable for preparing other D-ornithine compounds and aliphatic amine. The method for preparation comprises: mixing L-arginine or salt of the L-arginine with salicylal or derivant of the salicylal according to proportion, dissolving in alkaline or acidic dissolvant, obtaining DL-ornithine after racemization reaction, taking the DL-ornithine, biotransforming with microorganism or enzyme which contains lysine decarboxylase or ornithine decarboxylase under the temperature from 25DEG C to 45DEG C, obtaining the D-ornithine and the putrescine, then, using an isoelectric point crystallization method or a cation exchange resin separation method to separate the D-ornithine and the putrescine, and obtaining optically pure D-ornithine and putrescine. A chemical racemization method of the invention main takes water as the dissolvant, the catalyst consumption is little, the dissolvant which is used does not have poison and has low cost, the microorganism is easily cultured, and the invention is suitable for large scale industrial production.

The invention belongs to the technical field of chiral compounds biological transformation separation, in particular relates to a method for preparing chiral organic coumounds and a method for preparing D-ornithine and putrescine, and is also suitable for preparing other D-ornithine compounds and aliphatic amine. The method for preparation comprises: mixing L-arginine or salt of the L-arginine with salicylal or derivant of the salicylal according to proportion, dissolving in alkaline or acidic dissolvant, obtaining DL-ornithine after racemization reaction, taking the DL-ornithine, biotransforming with microorganism or enzyme which contains lysine decarboxylase or ornithine decarboxylase under the temperature from 25DEG C to 45DEG C, obtaining the D-ornithine and the putrescine, then, using an isoelectric point crystallization method or a cation exchange resin separation method to separate the D-ornithine and the putrescine, and obtaining optically pure D-ornithine and putrescine. A chemical racemization method of the invention main takes water as the dissolvant, the catalyst consumption is little, the dissolvant which is used does not have poison and has low cost, the microorganism is easily cultured, and the invention is suitable for large scale industrial production.

The invention provides a small molecule inhibitor containing 2,6-dihydroxypurine, the small molecule inhibitor is 1,3-dimethyl-8-(2-thienyl)-3,7-dihydro-1H- Purine-2,6-diketone, its structural formula is: the present invention will contain the 2,6-dihydroxypurine small molecule inhibitor in the application of inhibiting ornithine decarboxylase (ODC), and in the preparation of the drug for treating tumor application, and in the preparation of medicines for the treatment of pathogenic microorganism infections, and achieved remarkable results.

The invention provides a small molecule inhibitor containing dihydroacridine, the small molecule inhibitor is 2,2-dimethyl-N-(6-methyl-4-oxo-3,4-dihydro-2 ‑acridinyl) propionamide, the structural formula is the application of the small molecule inhibitor containing dihydroacridine in inhibiting ornithine decarboxylase (ODC) of the present invention, and the application in the preparation of drugs for treating tumors, and in The application in the preparation of medicines for the treatment of pathogenic microorganism infections has achieved remarkable results.

The present invention provides a kind of benzamide small molecule inhibitor, and this small molecule inhibitor is 2,3,4,5,6-pentafluoro-N-(3-fluoroalkenyl) benzamide, and structural formula is as follows: The present invention The application of the benzamide small-molecule inhibitor in inhibiting ornithine decarboxylase (ODC), in the preparation of a drug for treating tumors, and in the preparation of a drug for treating pathogenic microorganism infection has achieved remarkable effects.

The invention belongs to the field of biomedicine and relates to a small molecule inhibitor of ornithine decarboxylase (ODC) and an application thereof. A novel small molecule inhibitor aiming at ODC is found through computer-aided high-throughput medicine screening. Verification of the effects of the novel small molecule inhibitor finds that the novel small molecule inhibitor has good inhibiting effects on ODC and can be especially used for inhibiting human-derived ODC, preventing, treating and diagnosing tumor diseases and pathogenic microorganism infection and developing and preparing tumor medicines or medicines against pathogenic microorganism infection.

The invention belongs to the field of biomedicine and relates to a small molecule inhibitor of ornithine decarboxylase (ODC) and an application thereof. A novel small molecule inhibitor aiming at ODC is found through computer-aided high-throughput medicine screening. Verification of the effects of the novel small molecule inhibitor finds that the novel small molecule inhibitor has good inhibiting effects on ODC and can be especially used for inhibiting human-derived ODC, preventing, treating and diagnosing tumor diseases and pathogenic microorganism infection and developing and preparing tumor medicines or medicines against pathogenic microorganism infection.

The invention provides methods, uses and compounds for treating cancers. For example, certain embodiments provide a method for treating cancer in a mammal comprising administering to the mammal an effective amount of 3,5,7,8,4′-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. Certain other embodiments of the invention provide methods for inactivating ornithine decarboxylase (ODC) in a cell comprising contacting the cell in vitro or in vivo with an effective amount of 3,5,7,8,4′-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. The invention also provides a dermal product comprising 3,5,7,8,4′-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof, wherein the product prophylactically or therapeutically treats sunburn or other sun exposure and / or skin cancer in a mammal.